Rontalizumab

From Wikipedia, the free encyclopedia
Rontalizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized
Target IFN-α
Clinical data
Legal status ?
Identifiers
CAS number 948570-30-7 N
ATC code None
UNII LDO2FIQ61I YesY
Chemical data
Formula C6486H9990N1722O2026S44 
Mol. mass 145.9 kDa
 N (what is this?)  (verify)

Rontalizumab is a humanized monoclonal antibody[1] being developed by Genentech.[2] As of November 2009, it is being investigated in a clinical trial or the treatment of systemic lupus erythematosus.[3]

References

  1. ↑ WHO Drug Information
  2. ↑ Genentech: Rontalizumab (rhuMAb IFN alpha)
  3. ↑ ClinicalTrials.gov NCT00962832 A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus (ROSE)
Monoclonal antibodies for the immune system
Immune system ("-l(i[m])-")
Human ("-limu-")
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Inflammatory lesions ("-les-")
Mouse ("-leso-")

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug (L3/4)


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.